Selcaxen 40 mg (Selpercatinib) Capsules

Selcaxen (Selpercatinib) is a targeted anticancer medicine indicated for the treatment of adults with RET fusion-positive non-small cell lung cancer (NSCLC). It selectively inhibits RET kinase activity, helping to slow the growth and spread of cancer cells driven by RET gene alterations. Treatment should be initiated and supervised by a qualified healthcare professional after appropriate molecular testing confirms a RET gene fusion.

Therapeutic Effects

• Targets abnormal RET signaling pathways.
• Helps inhibit the growth of RET-driven cancer cells.
• Supports disease control in eligible patients with RET fusion-positive NSCLC.
• Provides precision-targeted therapy based on tumor genetic profiling.

Active Ingredient

• Selpercatinib

Strength

• 40 mg per capsule

Dosage Form

• Hard Gelatin Capsule

Pharmacological Class

• Selective RET Kinase Inhibitor

Therapeutic Class

• Targeted Anticancer Agent 

Recommended Adult Dose

The recommended dosage should be determined by a qualified healthcare professional based on the patient's body weight, clinical condition, and current prescribing guidelines. Always follow the prescribed treatment plan.

Administration Instructions

• Take the capsules exactly as prescribed.
• Swallow capsules whole with water.
• Do not crush, chew, or open the capsules.
• May be taken with or without food unless otherwise directed.
• Take doses at the same time each day to maintain consistent drug levels.

Missed Dose

• If a dose is missed, take it as soon as remembered unless the next scheduled dose is due within 6 hours. In that case, skip the missed dose and continue the regular schedule. Do not take two doses at the same time.

Important Administration Advice

• Continue treatment for as long as recommended by your healthcare provider.
• Regular clinical monitoring and laboratory assessments may be required during therapy.
• Do not change or discontinue treatment without medical advice.

Note: Dosage adjustments may be necessary in patients with adverse reactions, liver impairment, or when taking certain interacting medicines, as directed by the prescribing information and the treating physician.